ArticlePloS one2025
Global burden of major chronic respiratory diseases among older adults aged 55 and above from 1990 to 2021: Changes, challenges, and predictions amid the pandemic.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends in research of neuroimmune in lung diseases over past decade: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- COPD burden trends in China and G20 countries from GBD 2023 and Mendelian randomization.iScience · 2026Article
- Trend Analysis of Respiratory Disease Mortality in the Population Aged 65 and over in Poland: Results from a Registry Study (2000-2022).Advances in respiratory medicine · 2026Article
- SPG7-Mediated Regulation of mPTP and Mitochondrial Flickering in COPD: A Bioinformatics-Based Prediction of Mechanistic Framework.International journal of chronic obstructive pulmonary disease · 2026Article
- Discriminative feature learning for multiclass lung disease classification using contrastive learning.Frontiers in radiology · 2026Article
- Declining yet persistent asthma mortality among U.S. adults aged 65 years and older (1999-2020).Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize sex- and age-specific changes in the comprehensive burden of major chronic respiratory diseases (CRDs) and their attributable risk factors among adults aged ≥55 years globally, regionally, and nationally from 1990 to 2021 using the Global Burden of Disease (GBD) 2021 database.
methodsUtilizing the GBD 2021 database, we performed in-depth analyses and preliminary projections of global, regional, and national burden trends for chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung disease & pulmonary sarcoidosis (ILD&PS) through multi-model approaches including but not limited to Age-Period-Cohort (APC) models, Joinpoint regression, and Bayesian Age-Period-Cohort (BAPC) modeling.
resultsThe overall global CRD burden among adults ≥55 years declined from 1990 to 2021. However, the Corona Virus Disease 2019 (COVID-19) pandemic differentially altered asthma and COPD prevalence and incidence trends globally: low Socio-demographic Index (SDI) regions experienced an accelerated increase in prevalence, while high SDI regions showed a steeper rise in incidence. High mortality and disability-adjusted life years (DALYs) rates remained concentrated in low-middle SDI regions, notably Asia and North America. Consequently, prevalent CRD cases in this age group reached 223 million (95% UI 206.5-241.5) in 2021-accounting for half of all-age cases-with 18.47 million incident cases (95% UI 16.97-20.11), causing 4.15 million deaths (95% UI 3.76-4.58) and 83.67 million DALYs (95% UI 77.49-90.36). Air pollution, smoking, obesity, and chronic cold exposure persistently influenced COPD and asthma prevalence across regions and sexes.
conclusionThe pandemic shifted global CRD burden trends, particularly for asthma followed by COPD. Concurrent with global aging, burden trajectories across SDI levels raise concerns. As COVID-19 becomes endemic, older adults will experience impacts from recurrent viral infections, increasingly manifesting in coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.